FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149058047> ?p ?o ?g. }

• W2149058047 endingPage "401" @default.
• W2149058047 startingPage "393" @default.
• W2149058047 abstract "The treatment of acute myeloid leukemia of older, medically non-fit patients still poses a highly unmet clinical need, and only few large, prospective studies have been performed in this setting. Given the established activity of hypomethylating agents such as 5-aza-2'-deoxycytidine (decitabine) in myelodysplastic syndromes and acute myeloid leukemia with 20-30% bone marrow blasts, we investigated whether this drug is also active in patients with more than 30% blasts.To evaluate the efficacy and toxicity of decitabine in patients over 60 years old with untreated acute myeloid leukemia ineligible for induction chemotherapy, 227 patients (median age, 72 years), many with comorbidities, adverse cytogenetics and/or preceding myelodysplastic syndrome were treated with this hypomethylating agent. During the initial decitabine treatment (135 mg/m(2) total dose infused intravenously over 72 hours every 6 weeks), a median of two cycles was administered (range, 1-4). All-trans retinoic acid was administered to 100 patients during course 2. Fifty-two patients who completed four cycles of treatment subsequently received a median of five maintenance courses (range, 1-19) with a lower dose of decitabine (20 mg/m(2)) infused over 1 hour on 3 consecutive days every 4-6 weeks.The complete and partial remission rate was 26%, 95% CI (20%, 32%), and an antileukemic effect was noted in 26% of patients. Response rates did not differ between patients with or without adverse cytogenetics; patients with monosomal karyotypes also responded. The median overall survival from the start of decitabine treatment was 5.5 months (range, 0-57.5+) and the 1-year survival rate was 28%, 95%CI (22%,34%). Toxicities were predominantly hematologic.Decitabine is well tolerated by older, medically non-fit patients with acute myeloid leukemia; myelosuppression is the major toxicity. The response rate and overall survival were not adversely influenced by poor-risk cytogenetics or myelodysplastic syndrome. Because of these encouraging results, randomized studies evaluating single-agent decitabine versus conventional treatment are warranted. The study is registered with the German Clinical Trials Registry, number DRKS00000069." @default.
• W2149058047 created "2016-06-24" @default.
• W2149058047 creator A5011540358 @default.
• W2149058047 creator A5012072301 @default.
• W2149058047 creator A5013231760 @default.
• W2149058047 creator A5018920707 @default.
• W2149058047 creator A5042780466 @default.
• W2149058047 creator A5043494139 @default.
• W2149058047 creator A5043852143 @default.
• W2149058047 creator A5047951694 @default.
• W2149058047 creator A5053983155 @default.
• W2149058047 creator A5059825355 @default.
• W2149058047 creator A5061031803 @default.
• W2149058047 creator A5062688084 @default.
• W2149058047 creator A5063181849 @default.
• W2149058047 creator A5063615217 @default.
• W2149058047 creator A5067271311 @default.
• W2149058047 creator A5077123460 @default.
• W2149058047 creator A5079124367 @default.
• W2149058047 creator A5080642891 @default.
• W2149058047 creator A5089395073 @default.
• W2149058047 date "2011-11-04" @default.
• W2149058047 modified "2023-10-17" @default.
• W2149058047 title "A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy" @default.
• W2149058047 cites W1511596951 @default.
• W2149058047 cites W1879966002 @default.
• W2149058047 cites W1963919702 @default.
• W2149058047 cites W1966010937 @default.
• W2149058047 cites W1968081648 @default.
• W2149058047 cites W1969569267 @default.
• W2149058047 cites W1970772467 @default.
• W2149058047 cites W1972047494 @default.
• W2149058047 cites W1976961324 @default.
• W2149058047 cites W1980451195 @default.
• W2149058047 cites W1991858306 @default.
• W2149058047 cites W2007042448 @default.
• W2149058047 cites W2020151485 @default.
• W2149058047 cites W2022240113 @default.
• W2149058047 cites W2022733644 @default.
• W2149058047 cites W2025213305 @default.
• W2149058047 cites W2029409133 @default.
• W2149058047 cites W2034058960 @default.
• W2149058047 cites W2034295250 @default.
• W2149058047 cites W2043216151 @default.
• W2149058047 cites W2043244590 @default.
• W2149058047 cites W2048159897 @default.
• W2149058047 cites W2050736448 @default.
• W2149058047 cites W2068556430 @default.
• W2149058047 cites W2082865597 @default.
• W2149058047 cites W2086651719 @default.
• W2149058047 cites W2086990980 @default.
• W2149058047 cites W2094285350 @default.
• W2149058047 cites W2097035477 @default.
• W2149058047 cites W2104076485 @default.
• W2149058047 cites W2106082819 @default.
• W2149058047 cites W2106658124 @default.
• W2149058047 cites W2109771427 @default.
• W2149058047 cites W2116858301 @default.
• W2149058047 cites W2117446917 @default.
• W2149058047 cites W2124003772 @default.
• W2149058047 cites W2126572589 @default.
• W2149058047 cites W2128812336 @default.
• W2149058047 cites W2141939962 @default.
• W2149058047 cites W2145750252 @default.
• W2149058047 cites W2157287007 @default.
• W2149058047 cites W2160968219 @default.
• W2149058047 cites W2161186281 @default.
• W2149058047 cites W2164912656 @default.
• W2149058047 cites W2170631527 @default.
• W2149058047 cites W2170846829 @default.
• W2149058047 cites W2185856844 @default.
• W2149058047 doi "https://doi.org/10.3324/haematol.2011.048231" @default.
• W2149058047 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3291594" @default.
• W2149058047 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22058219" @default.
• W2149058047 hasPublicationYear "2011" @default.
• W2149058047 type Work @default.
• W2149058047 sameAs 2149058047 @default.
• W2149058047 citedByCount "204" @default.
• W2149058047 countsByYear W21490580472012 @default.
• W2149058047 countsByYear W21490580472013 @default.
• W2149058047 countsByYear W21490580472014 @default.
• W2149058047 countsByYear W21490580472015 @default.
• W2149058047 countsByYear W21490580472016 @default.
• W2149058047 countsByYear W21490580472017 @default.
• W2149058047 countsByYear W21490580472018 @default.
• W2149058047 countsByYear W21490580472019 @default.
• W2149058047 countsByYear W21490580472020 @default.
• W2149058047 countsByYear W21490580472021 @default.
• W2149058047 countsByYear W21490580472022 @default.
• W2149058047 countsByYear W21490580472023 @default.
• W2149058047 crossrefType "journal-article" @default.
• W2149058047 hasAuthorship W2149058047A5011540358 @default.
• W2149058047 hasAuthorship W2149058047A5012072301 @default.
• W2149058047 hasAuthorship W2149058047A5013231760 @default.
• W2149058047 hasAuthorship W2149058047A5018920707 @default.
• W2149058047 hasAuthorship W2149058047A5042780466 @default.
• W2149058047 hasAuthorship W2149058047A5043494139 @default.
• W2149058047 hasAuthorship W2149058047A5043852143 @default.

• next